+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 85Years
All Genders
ID05549752

Comparing Flecainide and Amiodarone for Treating Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease Without Ongoing Ischemia and Preserved Heart Function

Led by Hippocration General Hospital · Updated on 2025-06-13

80

Participants Needed

3

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of two antiarrhythmic drugs, flecainide and amiodarone, for cardioversion of paroxysmal atrial fibrillation in patients with coronary artery disease who do not have residual ischemia and have an ejection fraction above 35%. This trial aims to determine if flecainide is superior to amiodarone in successfully restoring normal heart rhythm and whether its safety is comparable. The study also seeks to assess if flecainide reduces hospital admissions, shortens the time to cardioversion, and decreases the need for electrical cardioversion. Participants will be randomly assigned to receive either intravenous flecainide or amiodarone in the Emergency Department. Flecainide is given as 2.0 mgkg over 10 minutes, while amiodarone is administered at 5.0-7.0 mgkg over 1 hour, followed by a maintenance dose for up to 24 hours. All patients will be monitored continuously with ECG for six hours after treatment starts, and a 24-hour Holter monitor will be placed. Patients stay in the Emergency Department for six hours post-treatment and are discharged if no adverse events occur otherwise, hospitalization is required. During the study, patients will have follow-up visits 24 hours after treatment for physical exams, ECG, cardiac ultrasound, and removal of the Holter monitor, with evaluation of any adverse effects. At 30 days, a phone call follow-up will be conducted to review outcomes and any side effects. The primary outcomes include the rate of successful cardioversion within six hours and the presence of specific heart rhythm abnormalities or low blood pressure. Secondary outcomes include discharge rates in normal rhythm, cardioversion success over 24 hours, time to cardioversion, frequency of electrical cardioversion, arrhythmia burden, and adverse events over 30 days.

CONDITIONS

Brief Title

Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia

Research Team

K

Konstantinos P Tsioufis, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here